Sequencing study of NBV-MB control group and MENK-NBV-MB group

RAW264.7 cells were divided into NBV-MB control group and MENK-NBV-MB group. Macrophages infected with NBV-MB were treated with MENK prophylactic intervention. The purpose of this study was to explore the immunological mechanism of MENK regulation of macrophages against NBV-MB, provide data support for MENK to become a new drug or vaccine adjuvant for NBV, and provide new ideas for clinical reovirus prevention and treatment Divide RAW264.7 cells into the NBV-MB control group and the MENK-NBV-MB group. The NBV-MB group is infected with RAW264.7 cells at a multiplicity of infection (MOI) of 30, while the MENK concentration is 10 mg/ml. Extract total RNA from the cells using the Trizol method, and quantify the total RNA precisely with the Qubit RNA assay kit. After processing, convert the total RNA samples into libraries suitable for sequencing on the Illumina® platform. Utilize RNA-Seq technology to detect transcriptome levels in the three sample groups.

将RAW264.7细胞分为NBV-MB对照组与MENK-NBV-MB组，对感染NBV-MB的巨噬细胞施加MENK预防性干预。本研究旨在探讨MENK调控巨噬细胞抗NBV-MB的免疫机制，为MENK成为针对NBV的新型药物或疫苗佐剂提供数据支撑，并为临床呼肠孤病毒的防治提供新思路。随后将RAW264.7细胞分为NBV-MB对照组与MENK-NBV-MB组：其中NBV-MB组以感染复数（multiplicity of infection, MOI）为30的感染量感染RAW264.7细胞，MENK干预浓度设置为10 mg/ml。采用Trizol法提取细胞总RNA，并通过Qubit RNA检测试剂盒对总RNA进行精确定量。完成样本处理后，将总RNA样本构建为适配Illumina®平台测序的文库。利用RNA-Seq技术检测三组样本的转录组水平。